VocaVibe
AI-diagnosis and Monitoring of Parkinson’s disease Using Voice
Company Overview
Snapshot
Founded in June 2023 by Dr. Ariel Schiff, Dr. Alon Shapira, Prof. Tanya Gurevich, and Dr. Yael Manor, VocaVibe operates with 1–10 employees. The company has raised $1 million across one funding round from eHealth Ventures. VocaVibe is currently in the clinical trial stage with its product, VocApp, focusing on AI-driven diagnostics for Parkinson's disease.
Business overview
VocaVibe is developing non-invasive, AI-driven diagnostic and monitoring solutions for Parkinson's disease (PD) using vocal biomarkers. Its core technology leverages artificial intelligence, including deep learning, machine learning, natural language processing, and voice & speech recognition, along with acoustic sensing. The company aims to provide early and accurate diagnosis, continuous real-time monitoring of disease progression, and treatment efficacy. VocaVibe serves the healthcare and life sciences sectors, targeting providers, patients, and insurance companies to enhance patient management, improve quality of life, and reduce healthcare costs.
Company Intelligence Q&A
- When was VocaVibe founded?
- VocaVibe was founded in June 2023.
- Who are the founders of VocaVibe?
- The founders of VocaVibe are Dr. Ariel Schiff (CEO), Dr. Alon Shapira (CTO), Prof. Tanya Gurevich (Clinical Consultant), and Dr. Yael Manor (Consultant).
- What is VocaVibe's primary product?
- VocaVibe's primary product is VocApp, which is currently in the clinical trial stage.
- What is VocaVibe's total disclosed funding?
- In June 2023, VocaVibe raised $1 million in a Pre-Seed round from eHealth Ventures.
- Which investor participated in VocaVibe's funding round?
- In June 2023, eHealth Ventures participated in VocaVibe's Pre-Seed funding round, which raised $1 million.